Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN)
Status:
Not yet recruiting
Trial end date:
2026-12-30
Target enrollment:
Participant gender:
Summary
This is a phase 3 study to evaluate effects on proteinuria and glomerular filtration rate of
sibeprenlimab 400 mg subcutaneously (s.c.) Q 4 weeks in adults with IgAN who are receiving
maximally tolerated standard-of-care therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.